Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PTGS2 | P35354 | 4/20 | 0.36 |
| ▸ | GPR84 | Q9NQS5 | 4/20 | 0.34 |
| ▸ | PAK1 | Q13153 | 1/20 | 0.34 |
| ▸ | THRB | P10828 | 1/20 | 0.33 |
| ▸ | CYP2C9 | P11712 | 2/20 | 0.33 |
| ▸ | CYP2C19 | P33261 | 2/20 | 0.33 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.33 |
| ▸ | CYSLTR2 | Q9NS75 | 1/20 | 0.32 |
| ▸ | CYSLTR1 | Q9Y271 | 1/20 | 0.32 |
| ▸ | SOAT1 | P35610 | 4/20 | 0.31 |
| ▸ | XDH | P47989 | 1/20 | 0.31 |
| ▸ | TLR8 | Q9NR97 | 1/20 | 0.31 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL601383 | 0.88 | PTGS2 (0.32) | PTGS2 | |
| SCHEMBL600645 | 0.82 | KDM4E (0.34) | PTGS2 | |
| SCHEMBL600158 | 0.81 | CYP2C9 (0.42) | PTGS2GPR84CYP2C9CYP2C19CYP1A2 | |
| SCHEMBL600516 | 0.77 | PTGS2 (0.52) | PTGS2 | |
| SCHEMBL11798763 | 0.75 | PTGS2 (0.39) | PTGS2GPR84PAK1THRBCYP2C9 | |
| SCHEMBL601317 | 0.69 | MAPT (0.36) | THRBCYP2C9CYP2C19CYP1A2TLR8 | |
| SCHEMBL8374078 | 0.67 | TYR (0.47) | PTGS2GPR84THRBCYSLTR2CYSLTR1 | |
| SCHEMBL28404539 | 0.66 | EPHX2 (0.50) | PTGS2CYSLTR2CYSLTR1 | |
| SCHEMBL28397899 | 0.66 | EPHX2 (0.50) | PTGS2CYSLTR2CYSLTR1 | |
| SCHEMBL28891540 | 0.66 | EPHX2 (0.50) | PTGS2CYSLTR2CYSLTR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2420500-A1 | PYRIDINE THIO DERIVATIVE, AND PHARMACEUTICAL COMPOSITION WHICH CONTAINS SAME AND HAS ANTI-HELICOBACTER PYLORI ACTION | aRigen Pharmaceuticals, Inc. (JP) | 2012-02-22 | — | — | EP | disclosed |
| US-20120041030-A1 | PYRIDINE THIO DERIVATIVE, AND PHARMACEUTICAL COMPOSITION WHICH CONTAINS SAME AND HAS ANTI-HELICOBACTER PYLORI ACTION | LINK GENOMICS, INC. (JP) | 2012-02-16 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120041030-A1 | PYRIDINE THIO DERIVATIVE, AND PHARMACEUTICAL COMPOSITION WHICH CONTAINS SAME AND HAS ANTI-HELICOBACTER PYLORI ACTION | TPMT, TST, PTPN11 | PTGS2 347/4885GPR84 3620/4885PAK1 2335/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.